Fendrick AM, Monto AS, Nightengale B, Sarnes M
Additionally, the reassuring safety findings further support the strong potential value of semaglutide in this population. Chronic kidney disease affects over 800 million people worldwide and is particularly prevalent among individuals with type 2 diabetes.2 Chronic kidney disease poses a significant risk of kidney failure, cardiovascular events and death,3 highlighting the critical need for research into its prevention and treatment
Prost M
If you and your provider decide to stop semaglutide, it is often recommended to gradually reduce the dose rather than stopping abruptly
Note: Supplements are intended to support an already established training and nutrition plan
Patients on semaglutide often experience less hunger, earlier fullness during meals, diminished cravings for high-calorie foods, increased energy for physical activity, and better-managed blood sugar levels